Miromatrix Medical (NASDAQ: MIRO), a prominent player in the Biotechnology industry, has been demonstrating a bullish trend in its stock performance, which is expected to continue into December. The company's shares have shown a steady increase, with the current quote at
$3.34, which is close to the 52-week high of
$4.5. Despite the company reporting a loss of
$30M from continuing operations, Wall Street analysts have set a target price of
$9 for the stock, indicating strong confidence in its
future performance. From a risk-adjusted perspective, Miromatrix's Sortino Ratio of
0.5989 suggests that the company has been able to provide satisfactory returns for
the level of risk it has taken on. Furthermore, the company's Treynor Ratio of
0.2451 indicates that it has generated decent
risk-adjusted returns when considering the systematic risk. However, investors should be cautious of the company's high standard deviation of
27.21, which indicates a high level of volatility in the stock's returns. Despite the company's negative net income, the number of shares shorted in the prior month was
527.2K, suggesting that
market sentiment towards the stock is bullish. The company's Price to Book ratio of
2.6176 is also within a reasonable range, indicating that the stock is not overvalued. Given these factors, it is likely that Miromatrix Medical's shares will continue their bullish trend in December.
Important Points
Miromatrix Medical has an average rating of 'Strong Buy' from one analyst. Is this consensus based on technical analysis? As we know, typical technical analysis involves the use of price momentum, patterns, and trends derived from historical prices. The goal is to identify signals based on the market sentiment of Miromatrix Medical investors, which reflects their perception of the company's future value. Let's delve into some aspects of Miromatrix's technical analysis. Approximately 24.0% of the company's outstanding shares are owned by corporate insiders. The book value of Miromatrix Medical is currently reported as 0.79. The company has recorded a loss per share of 1.26. It's important to note that Miromatrix Medical has not issued any dividends in recent years.
Using predictive
technical analysis, we can analyze different prices and returns patterns and
diagnose historical swings to determine the real value of Miromatrix Medical. In general, sophisticated investors focus on analyzing Miromatrix Medical stock price patterns and their correlations with different microeconomic environment and drivers. They apply predictive analytics to build Miromatrix Medical's daily price indicators and compare them against related drivers such as
momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional
technical analysis and
fundamental analysis, we attempt to find the most accurate representation of
Miromatrix Medical's intrinsic value. In addition to deriving basic predictive indicators for Miromatrix Medical, many experienced traders also check how macroeconomic factors affect Miromatrix Medical price patterns. Please read more on our
technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed
many market ups and downs, anticipate that the market will even out over time. This tendency of Miromatrix Medical's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Watch out for price decline
Please consider monitoring Miromatrix Medical on a daily basis if you are holding a position in it. Miromatrix Medical is trading at a penny-stock level, and the possibility of delisting is much higher compared to other delisted stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as Miromatrix Medical stock to be traded above the $1 level to remain listed. If Miromatrix Medical stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How does Miromatrix Stands against Peers?
Analyzing Miromatrix Medical competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Miromatrix Medical across multiple sectors and
thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be. Check out
Miromatrix Medical Competition DetailsCloser look at Miromatrix Medical Standard Deviation
Miromatrix Medical has current Standard Deviation of 27.21. The Standard Deviation is a measure of how spread out the prices or returns of an asset are on average. It is the most widely used risk indicator in the field of investing and finance. Standard Deviation is commonly used to measure confidence in statistical conclusions regarding certain equity instruments or portfolios of equities.
Standard deviation is applied to the annual rate of return of an investment to measure the investment's volatility. Standard deviation is also known as historical volatility and is used by investors as a gauge for the amount of expected market volatility. A large standard deviation usually indicates that the data points are far from the mean and a small standard deviation indicates that they are clustered closely around the mean.
Standard Deviation | = | SQRT(V) |
| = | 27.21 |
Let's now compare Miromatrix Medical Standard Deviation to its closest peers:
| MIRO | 27.209504698106397 |
| HNFSB | 0.46 |
| NIPMY | 0.008157 |
| SIGRF | 0.76 |
| SSYS | 2.92 |
Every cloud has a silver lining, and the silver lining for Miromatrix Medical (NASDAQ: MIRO) is its bullish trend, despite a challenging financial landscape.
The biotechnology company has seen a steady uptick in its 50-day moving average, which stands at 1.48, while its 200-day moving average is at 1.68. This indicates a positive momentum, which could continue into December. However, the company's
financial health is a cause for concern. With a net income showing losses of 30M and an operating income showing losses of 30.2M, profitability is a challenge. Yet, Miromatrix Medical's current ratio is at an impressive
9.09X, indicating the company's strong ability to meet its short-term obligations. The company's market capitalization stands at
91.58M, reflecting its perceived value by the market. Despite the financial challenges, the company's shares are expected to continue their bullish trend, given the favorable technicals. .
Miromatrix is expecting lower volatility in December
Miromatrix Medical Inc., a notable entity in the biotechnology sector, is currently exhibiting signs of decreased volatility as we transition into December. The potential upside of the stock has been revised downwards to 10.61, signaling a more stable and less risky investment landscape. This revision implies that investors can anticipate fewer price swings, thus providing a more predictable investment prospect. Despite the reduced upside, Miromatrix remains a worthwhile investment, particularly for those seeking stability in the typically volatile biotech sector. Miromatrix Medical is demonstrating above-average volatility over the chosen time period. Investors are advised to examine Miromatrix Medical independently to ensure that their intended
market timing strategies align with their expectations about Miromatrix Medical's volatility. Understanding varying
market volatility trends often assists investors in timing the market. The correct use of volatility indicators allows traders to gauge Miromatrix Medical's stock risk against market volatility during both bullish and bearish trends. The heightened level of volatility that accompanies bear markets can directly affect
Miromatrix Medical's stock price, adding stress to investors as they witness the value of their shares plummet. This typically compels investors to rebalance their portfolios by purchasing different stocks as prices decline.
Our Final Take On Miromatrix Medical
Although some companies within the biotechnology industry are still a little expensive, even after the recent corrections, Miromatrix Medical may offer a potential longer-term growth to insiders. With an impartial outlook on the current market volatility, it may be better to hold off any inventment activity and neither buy nor drop any shares of Miromatrix Medical at this time. The Miromatrix Medical risk-reward trade off is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Miromatrix Medical.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Rifka Kats is a Member of Macroaxis Editorial Board. Rifka writes about retail product and service companies from the perspective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of Miromatrix Medical. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com